22 May 06
DailyUpdates 18th May, 2006: As the antidepressant sector continues to go through a period of turbulance we report on new data for one blockbuster from this class - Lexapro. Selected for special mention from over 50 journal articles today's feature demonstrates great timing appearing at the same time as our feature - Major Depressive Disorder. Today's edition of DailyUpdates can be seen here
17 May 06
Despite almost 200 million people suffering from hypertension in the seven major pharmaceutical markets alone, according to a new report, innovation is scarce within antihypertensive R&D. What little innovation that does exist is being delivered by Novartis, which is set to launch two new antihypertensives in 2007 in the shape of oral renin inhibitor Rasilez, and the 'two-in-one' pill Exforge.
17 May 06
EntreMed has initiated a phase II trial of Panzem in combination with Genentech's Avastin in carcinoid cancer. The trial will examine how the therapy fares against potential rivals and its possible use in other tumor types. With the blockbuster Avastin possessing the potential to significantly raise the profile of Panzem, the study will prove crucial for EntreMed's lead pipeline drug candidate.
15 May 06
DailyUpdates 15th May, 2006: Amongst the 50 or so papers and press releases featured today two focusing on VEGF jump out as being of especial interest. The first, a paper published by Stanford University, reports on the anti-cancer activity of an oncolytic virus in combination with gene therapy. The virus was engineered to selectively replicate in and kill cancer cells . The gene therapy encoded a soluble version of Flk1, one of the VEGF receptors. The two approaches together produce effective a
15 May 06
When not doing 'insane sports', Amgen's Europe chief Rolf Hoffmann is battling big pharma
13 May 06
This summit aims to provide both strategic and practical information that will ensure that organisations can prepare for and survive what is now considered to be the inevitable pandemic. Professor Hugh Pennington from the Department of Medical Microbiology at University of Aberdeen will repeat his warning that, â€śOnly one thing is certain and that is that there will be a pandemic.â€ť
11 May 06
A new report estimates that there will be approximately 84,000 cases of adult and childhood leukemia in the world's seven major pharmaceutical markets in 2006. Acute leukemias will account for 43% of these cases, and, although this market is relatively small compared to other cancer types, the clear unmet needs and regulatory incentives should help encourage drug makers.
10 May 06
This Conference will provide a platform for intellectual discourse in order to answer these questions and to discuss other pressing issues regarding the pharmaceutical industry in China in particular, and the world in general. Opportunities and challenges within the whole value chain, from research and development down to sales and marketing will be discussed and solutions put forward for the benefits of attendees.
IBG Company Limited
30 Mar 06
Why ? Decision makers were not aware of the ROI that can have a search engine marketing strategy.
29 Mar 06
The antidyslipidemics market is driven by the statins, which account for 87% of this segment. However, as many statins are expected to face patent expiry in the coming decade manufacturers are looking to novel products to protect their franchise. Such products include combination such as Pfizer's atorvastatin/torcetrapib. Studies demonstrating that higher doses of existing products can offer improved efficacy but with no increase in side-effects will also help optimize sales in the antidyslipid
28 Mar 06
Heart failure affects more than 5 million people in the U.S. Approximately 20% of hospitalizations are due to acute congestive heart failure translating into a health-care system cost of $15 billion. Given the paucity of the pipeline for acute congestive heart failure, the best hope of clinical improvement will involve improved utilization of existing therapies. However early intervention requires rapid and accurate diagnosis. Given its diagnostic potential, the measurement of plasma BNP a
22 Mar 06
According to our recent feature Pain Therapeutics 2005 the value of the pharmaceutical market for pain relief approached $23 billion in 2004.Â The pain market can be divided into acute pain which is well served by OTC medications, post-operative pain and chronic pain. One of the most challenging areas of analgesia is the treatment of chronic neuropathic pain.Â Cancer pain also represents a largely unmet market which along with post-operative analgesia depends to a large extent on opioid-based th
21 Mar 06
If Sales Force Effectiveness is high on your agenda in the current climate, then donâ€™t miss Pharma IQâ€™s Next Generation Pharmaceutical Sales Strategies event in June. Learn from speakers who have effectively increased their sales force ROI & successfully implemented alternative options to drive sales effectiveness.
01 Mar 06
Genentech and Biogen Idec announced yesterday that the FDA has approved Rituxan (Rituximab) for use as a treatment of rheumatoid arthritis. Hopefully this news will mark the start of a new era in the treatment of autoimmune disease.
28 Feb 06
ICONâ€™s core competency is project management, built up over the last fifteen years managing complex projects and underpinned by comprehensive and consistent processes which conform to the ISO9001:2000 quality certification.
24 Feb 06
Abbott recently had the largest gain in reputation of any company in its industry
when Fortune magazine ranked it number three in the magazineâ€™s list of the
most admired companies in the United States â€“ Fortuneâ€™s highest ranking for
Abbott since 1989. How was this achieved and what factors led up to it?
24 Feb 06
In an increasingly complex world, with significant changes taking place on a social,
commercial and economic basis almost weekly, corporate social responsibility is a
priority for Abbott as it engages its stakeholders, advances its core objectives and
exercises its influence â€“ making productive contribution to the societies and
communities it operates in.
21 Feb 06
Today's edition of DailyUpdates features work conducted by Imperial College researchers who have identified an aptamer able to reduce the proliferation of lymphoma cells by 40%. This work represents a licensing opportunity. The aptamer is of potential therapeutic use and may be of interest to companies with an interest in biologic approach to oncology. The aptamers also forms the basis of a HTS assay that should help identify small molecule therapeutics for the treatment of hematological cancers
10 Feb 06
The approval of Novartisâ€™ Glivec in 2001 represents one of the real success stories in the treatment of Chronic myeloid leukaemia. Already generating $2.2 billion in global sales (2005 figures), Glivec is Novartisâ€™ second highest revenue generator and the continued development of this blockbuster seems certain to increase these figures still further. Here we focus on clinical studies aimed at advancing Gleevec as a treatment of small-cell lung cancer
09 Feb 06
The prevalence of obesity has increased by 61% in the US during the period 1991-2001. According to Datamonitorâ€™s report, Obesity - commercial opportunities and therapeutic pipeline analysis 127m people were classified obese in the seven major markets in 2003. Obesity is an active area of R&D and numerous novel molecular targets are currently being evaluated. One target, ghrelin was the subject of a major target discovery report from LeadDiscovery published in 2003 Ghrelin: Pharmaceutical & Ther
03 Feb 06
The size of the cytotoxic market in the seven major pharmaceutical markets is estimated to be approximately $9.6 billion. Datamonitor expects it to reach a peak of $12.8 billion by 2009. However, mainly due to major patent expiries, it is expected to drop to $11.3 billion by 2014. Topoisomerase inhibitors represent a subgroup of the plant alkaloid class of cytotoxics. DNA topoisomerase II inhibitors are among the most efficacious drugs for the treatment of cancer although they are associated wi
03 Feb 06
The market for antibacterials, valued at $24 billion in the seven major markets, faces significant revenue loss in the period 2005-2007 due to major patent expiries. In exception, considerable success has been met by those targeting drug resistant infections. This is highlighted by the rapid uptake of products focused on drug-resistant infections, such as Pfizer's Zyvox (linezolid). Here we highlight a promising early stage candidate being developed by Replidyne, REP8839
31 Jan 06
OX40 (CD134) is one of the newer tumor necrosis factor receptor (TNFR) family members. Expressed on CD4+ T-cells, its activation by OX40L, a type II membrane protein expressed on activated B-cells, dendritic cells and macrophages, plays an important T-cell co-stimulatory role. Today we highlight additional involvement in heart disease
25 Jan 06
Genomics and proteomics comprise a fundamental area of bioinformatics however exploiting the wealth of information gained using such disciplines remains a rate limiting step in the drug discovery process. Todayâ€™s edition of DailyUpdates (Jan 25th 2005) describes ground breaking work that has allowed researchers to identify candidate therapeutics for the treatment of SARs virus infection in under a month using the virus genome as a starting point